BTIG raised the firm’s price target on Cartesian Therapeutics (RNAC) to $44 from $42 and keeps a Buy rating on the shares. The firm cites the ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...

Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Preliminary data from Phase 2 trial of Descartes-08 in systemic ...

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...

Cartesian Therapeutics (RNAC) announced positive initial data from its ongoing Phase 2 open-label trial of Descartes-08 in patients with systemic ...